Innovative approaches to overcoming challenges in oncology R&D

Despite incredible progress in oncology R&D, unmet needs persist, particularly for cancers that are difficult to treat—like pancreatic and small cell lung cancer. While oncology R&D investment is high, the return on that investment is often challenging, considering high failure rates, lengthy development timelines and regulatory pressures.

This webinar introduces the idea of “increasing the size of the top of the asset funnel” by developing assets as platforms, increasing the diversity of therapeutic modality-target intersections, tumor-agnostic approaches, early-stage acquisitions and novel combinations. We’ll also explore how we can use AI to develop de novo compounds and find new purposes for existing compounds as potential solutions to these unmet needs.

We’ll unpack key learnings, including:

• The greatest areas of unmet need in oncology and the obstacles that are impeding further advancement in oncology R&D
• How the industry is addressing these obstacles through increasing the size of the top of the asset funnel
• And how you can tailor the asset funnel to your organization’s pipeline and capabilities